Figures & data
Figure 1. Mean plaque IGA scores of HP/TAZ–treated and untreated plaques through week 12. HP/TAZ, halobetasol propionate 0.01% and tazarotene 0.045%; IGA, investigator’s Global Assessment. aOne of the 10 enrolled subjects was removed for protocol violation and not included in analyses. bTwo subjects maintained an IGA score of 0 from week 8 to week 12. **p < 0.005, ***p < 0.001, treated compared to untreated plaques (n = 9).
Figure 2. Psoriatic plaques treated with HP/TAZ improved from baseline to week 12 compared to untreated plaques. Patient consent was obtained for the use of all photographs. HP/TAZ, halobetasol propionate 0.01% and tazarotene 0.045%.
Figure 3. Mean TNF-α levels in HP/TAZ–treated and untreated plaques. HP/TAZ, halobetasol propionate 0.01% and tazarotene 0.045%; TNF-α, tumor necrosis factor alpha. aOne of the 10 enrolled subjects was removed for protocol violation and not included in analyses. bControl: D-squame tape was taken from a healthy volunteer without psoriasis. *p < 0.05, treated compared to untreated plaques (n = 9).
Figure 4. Mean IL-17A levels in HP/TAZ–treated and untreated plaques. HP/TAZ, halobetasol propionate 0.01% and tazarotene 0.045%; IL-17A, interleukin 17 A. aOne of the 10 enrolled subjects was removed for protocol violation and not included in analyses. bControl: D-squame tape was taken from a healthy volunteer without psoriasis. *p < 0.05, treated compared to untreated plaques (n = 9).
Data availability statement
Data available upon reasonable request of the corresponding author.